CD276 and cancer: A RAS inhibitor has the potential to stimulate the immune system by decreasing the RAS‐MAPK signaling pathway resulting in a decrease in PD‐L1 and/or B7‐H3 expression on the surface of cancer cells, which favors T‐cell antitumor activity (Figure 2).